CBLIF and synovial sarcoma: Indeed, defective DDRs influence both the anti-tumor immune-response by activating the INF pathway (40) and the immune-surveillance, through the accumulation of neo-antigens induced by expressed somatic mutations (38, 39) that can enhance the efficacy of immune-checkpoint (IC) inhibitors, therapeutics also used to treat SS (50).